Dr. Patel co-authored two papers linking the antimalarial drug hydroxychloroquine to higher mortality rates in COVID-19 patients in The Lancet and the New England Journal of Medicine. The papers drew widespread concern, causing the World Health Organization to suspend its clinical trial on hydroxychloroquine to further examine the drug’s safety. Both journals retracted the papers June 4 after questions of accuracy arose surrounding the papers’ data source, analytics company Surgisphere.
Dr. Patel’s affiliation with the university was listed on both of the retracted papers. A spokesperson declined to comment on the motivation behind the university’s decision, telling STAT, “The University of Utah does not comment on reasons surrounding termination of academic appointments.”
More articles on pharmacy:
Remdesivir could make billions for Gilead, analyst says
FDA’s vaccine head quits Operation Warp Speed days after joining
Drug wholesale, net prices increasing at slower rate, study says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
